metabolicMolecular Weight: 0

Retatrutide

LY3437943

A triple agonist targeting GLP-1, GIP, and glucagon receptors for advanced metabolic control.

Shop Retatrutide

Mechanism

Triple agonist for GLP-1, GIP, and glucagon receptors. Provides superior metabolic control and weight loss.

Half-Life

5-6 days

Administration

Subcutaneous

Technical Protocol

Retatrutide: Comprehensive Research Guide

Overview

Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, representing the next generation of metabolic peptides.

Mechanism of Action

Activates GLP-1, GIP, and glucagon receptors
Provides superior weight loss
Improves metabolic parameters
Advanced glycemic control

This information is for research and educational purposes only.

Peer-Reviewed Citations

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for obesity

Jastreboff AM, et al. • N Engl J Med (2023)

Access Research

Frequently Asked Questions

What is Retatrutide?

A triple agonist targeting GLP-1, GIP, and glucagon receptors for advanced metabolic control.

How does Retatrutide work?

Triple agonist for GLP-1, GIP, and glucagon receptors. Provides superior metabolic control and weight loss.

What is the typical dosage of Retatrutide in research?

The typical research dosage of Retatrutide is 4-8 mg weekly (range: 1-12 mg weekly). Common administration routes include Subcutaneous.

How should Retatrutide be stored?

Store at 2-8°C, protect from light

Source Retatrutide for Your Research

Third-party tested, EU-shipped, certificate of analysis included. High-purity Retatrutide available from our verified research partner.